(BIM) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 23, 2013
(Benzinga,
11/4/10)
bioMerieux and Biocartis announced today that they have entered into a strategic agreement to co-develop assays on Biocartis' fully integrated molecular diagnostics system, which the two companies will co-distribute starting in 2012....(read more)
(Hedge Fund Blogs From HedgeCo.Net,
6/17/09)
West Palm Beach (HedgeCo.net) - Bullman Investment Management (BIM), headed by Nick Bullman, has officialy launched the Bullman Global Fund, a global multi-strategy hedge fund...(read more)
BIOMERIEUX (BIM-FR) Company Overview
There is no analysis for BIM yet. But you can go to Wikinvest to help create one!
What's in this BIM analysis on Wikinvest...
- Company Overview
- Major Product Segments
- Microbiology (52% of sales)
- Immunoassays (28% of sales)
- Industrial Applications (15% of sales)
- Molecular Diagnostics (5% of sales)
- Business Growth
- FY 2009[8]
- Trends and Forces
- Diagnostics transitioning from laboratory to clincal tests
- BioMérieux's aims to expand in international markets
- The rise of Personalized Medicine in health care affects bioMérieux's theranostics division
- The success of the bioMérieux's recent collaborations and acquisitions will impact its valuation
- Competition
- References
